Agenda

7:00 am

—

8:00 am

New Treatment Approaches Across Disease Settings for HER2-Expressing Breast Cancer

Breakfast and Non-CME/CE Bonus Presentation

New Treatment Approaches Across Disease Settings for HER2-Expressing Breast Cancer

Speaker: Kit Y. Lu, MD

8:00 am

—

8:05 am

Welcome and Introduction

Seth A. Wander, MD, PhD

8:05 am

—

9:45 am

Adam M. Brufsky, MD, PhD; Claudine Isaacs, MD, FRCPC; Arielle Medford, MD; Joyce Slingerland, MD, PhD

HR+

Session I

HR+

9:45 am

—

10:45 am

In ESR1-mutated, ER+/HER2- mBC following progression on ET

Refreshments and Non-CME/CE Bonus Presentation

In ESR1-mutated, ER+/HER2- mBC following progression on ET

ORSERDU® (elacestrant): Powerful efficacy in EMERALD@, now with published real-world evidence 1-3

Speaker: Adam Brufsky, MD, PHD, FACP

10:45 am

—

11:30 am

Break: Exhibit Hall Opens

11:30 am

—

12:55 pm

Katherine DiNardo, MD; Neil Iyengar, MD; Rebecca A. Shatsky, MD

HR+, Continued

Session I

HR+, Continued

12:55 pm

—

1:55 pm

Learn About a Treatment Option for Patients With HR+/HER2+ mBC

Lunch and Non-CME/CE Bonus Presentation

Learn About a Treatment Option for Patients With HR+/HER2+ mBC

Speaker: Priya Rudolph, MD, PhD

1:55 pm

—

2:10 pm

2:10 pm

—

3:15 pm

Kelly E. McCann, MD, PhD; Michael Press, MD, PhD

HER2+

Session II

HER2+

3:15 pm

—

3:45 pm

3:45 pm

—

5:10 pm

Manmeet Ahluwalia, MD, MBA, FASCO; Nan Chen, MD; Abirami Sivapiragasam, MD

HER2+, Continued

Session II

HER2+, Continued

5:10 pm

—

6:10 pm

An Overview of VEPPANU (vepdegestrant): The First-and-Only FDA-Approved PROTAC

Refreshments and Non-CME/CE Bonus Presentation

An Overview of VEPPANU (vepdegestrant): The First-and-Only FDA-Approved PROTAC

A PROTAC is a type of heterobifunctional protein degrader, a novel treatment class

Speaker: Wassim Mchayleh, MD, MBA, FACP

6:10 pm

—

Day One Adjourns

DAY 2

SATURDAY,

SEPTEMBER 19

6:30 am

—

7:00 am

—

8:00 am

A 2L Treatment Option for HR+/HER2- aBC or mBC with PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET +/- CDK4/6

Breakfast and Non-CME/CE Bonus Presentation

A 2L Treatment Option for HR+/HER2- aBC or mBC with PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET +/- CDK4/6

A Next-Generation 1L Approach in HR+/HER2- mBC: The Role of Early Intervention Upon Emergence of Endocrine Resistance

Speaker: Kit Lu, MD

8:00 am

—

8:15 am

Exhibit Hall Opens

8:15 am

—

10:00 am

Session III

General Medicine for Oncologists

Session III

General Medicine for Oncologists

Alexa Meara, MD; Neel Pasricha, MD; Afreen Shariff, MD; Daniel Zlotoff, MD, PhD

10:00 am

—

11:00 am

Pause Progression: An Emerging Approach Using an Oral ER Antagonist

Refreshments and Non-CME/CE Bonus Presentation

Pause Progression: An Emerging Approach Using an Oral ER Antagonist

Speaker: Lauren A. Mauro, MD

11:00 am

—

11:30 am

11:30 am

—

1:15 pm

Triple-Negative Breast Cancer

Session IV

Triple-Negative Breast Cancer

Natasha Hunter, MD; Jane Meisel, MD, FASCO; Priyanka Sharma, MD; Julia White, MD

1:15 pm

—

2:15 pm

Clinical applications of Cerianna (FES) PET/CT: A case-based perspective

Lunch and Non-CME/CE Bonus Presentation

Clinical applications of Cerianna (FES) PET/CT: A case-based perspective

Speaker: Kit Lu, MD

2:15 pm

—

2:30 pm

2:30 pm

—

4:15 pm

Triple Negative, Continued

Session IV

Triple Negative, Continued

Steven Isakoff, MD, PhD; MIchelle Melisko, MD; Rima Patel, MD; Cesar A. Santa-Maria, MD

4:15 pm

—

4:30 pm

Break (Virtual Conference Adjourns)

4:30 pm

—

5:30 pm

Tumor Board (in-person only)

‍Steven Isakoff, MD, PhD, MMSc; Seth A. Wander, MD, PhD

5:30 pm

—

Conference Adjourns

Please note all sessions are listed in Eastern Time. Agenda and credit amount subject to change.

Download Agenda

DAY 1

FRIDAY,

SEPTEMBER 18

6:30 am

—

7:00 am

—

8:00 am

New Treatment Approaches Across Disease Settings for HER2-Expressing Breast Cancer

Breakfast and Non-CME/CE Bonus Presentation

New Treatment Approaches Across Disease Settings for HER2-Expressing Breast Cancer

Speaker: Kit Y. Lu, MD

8:00 am

—

8:05 am

Welcome and Introduction

Seth A. Wander, MD, PhD

8:05 am

—

9:45 am

Adam M. Brufsky, MD, PhD; Claudine Isaacs, MD, FRCPC; Arielle Medford, MD; Joyce Slingerland, MD, PhD

HR+

Session I

HR+

9:45 am

—

10:45 am

In ESR1-mutated, ER+/HER2- mBC following progression on ET

Refreshments and Non-CME/CE Bonus Presentation

In ESR1-mutated, ER+/HER2- mBC following progression on ET

ORSERDU® (elacestrant): Powerful efficacy in EMERALD@, now with published real-world evidence 1-3

Speaker: Adam Brufsky, MD, PHD, FACP

10:45 am

—

11:30 am

Break: Exhibit Hall Opens

11:30 am

—

12:55 pm

Katherine DiNardo, MD; Neil Iyengar, MD; Rebecca A. Shatsky, MD

HR+, Continued

Session I

HR+, Continued

12:55 pm

—

1:55 pm

Learn About a Treatment Option for Patients With HR+/HER2+ mBC

Lunch and Non-CME/CE Bonus Presentation

Learn About a Treatment Option for Patients With HR+/HER2+ mBC

Speaker: Priya Rudolph, MD, PhD

1:55 pm

—

2:10 pm

2:10 pm

—

3:15 pm

Kelly E. McCann, MD, PhD; Michael Press, MD, PhD

HER2+

Session II

HER2+

3:15 pm

—

3:45 pm

3:45 pm

—

5:10 pm

Manmeet Ahluwalia, MD, MBA, FASCO; Nan Chen, MD; Abirami Sivapiragasam, MD

HER2+, Continued

Session II

HER2+, Continued

5:10 pm

—

6:10 pm

An Overview of VEPPANU (vepdegestrant): The First-and-Only FDA-Approved PROTAC

Refreshments and Non-CME/CE Bonus Presentation

An Overview of VEPPANU (vepdegestrant): The First-and-Only FDA-Approved PROTAC

A PROTAC is a type of heterobifunctional protein degrader, a novel treatment class

Speaker: Wassim Mchayleh, MD, MBA, FACP

6:10 pm

—

Day One Adjourns

Please note all sessions are listed in Eastern Time. Agenda and credit amount subject to change.

Download Agenda

DAY 2

SATURDAY,

SEPTEMBER 19

6:30 am

—

7:00 am

—

8:00 am

A 2L Treatment Option for HR+/HER2- aBC or mBC with PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET +/- CDK4/6

Breakfast and Non-CME/CE Bonus Presentation

A 2L Treatment Option for HR+/HER2- aBC or mBC with PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET +/- CDK4/6

A Next-Generation 1L Approach in HR+/HER2- mBC: The Role of Early Intervention Upon Emergence of Endocrine Resistance

Speaker: Kit Lu, MD

8:00 am

—

8:15 am

Exhibit Hall Opens

8:15 am

—

10:00 am

Session III

General Medicine for Oncologists

Session III

General Medicine for Oncologists

Alexa Meara, MD; Neel Pasricha, MD; Afreen Shariff, MD; Daniel Zlotoff, MD, PhD

10:00 am

—

11:00 am

Pause Progression: An Emerging Approach Using an Oral ER Antagonist

Refreshments and Non-CME/CE Bonus Presentation

Pause Progression: An Emerging Approach Using an Oral ER Antagonist

Speaker: Lauren A. Mauro, MD

11:00 am

—

11:30 am

11:30 am

—

1:15 pm

Triple-Negative Breast Cancer

Session IV

Triple-Negative Breast Cancer

Natasha Hunter, MD; Jane Meisel, MD, FASCO; Priyanka Sharma, MD; Julia White, MD

1:15 pm

—

2:15 pm

Clinical applications of Cerianna (FES) PET/CT: A case-based perspective

Lunch and Non-CME/CE Bonus Presentation

Clinical applications of Cerianna (FES) PET/CT: A case-based perspective

Speaker: Kit Lu, MD

2:15 pm

—

2:30 pm

2:30 pm

—

4:15 pm